Skip to Main Content


Skip Nav Destination
Issue Cover
Current Issue
Volume 137,
Issue 8,
February 25, 2021

Issue Highlights

Latest in Blood
Plenary Papers
Steven Le Gouill; Franck Morschhauser; David Chiron; Krimo Bouabdallah; Guillaume Cartron; Olivier Casasnovas; Caroline Bodet-Milin; Sylviane Ragot; Céline Bossard; Nathalie Nadal; Charles Herbaux; Benoit Tessoulin; Emmanuelle Tchernonog; Cédric Rossi; Rory McCulloch; Thomas Gastinne; Mary B. Callanan; Simon Rule
DOI: 10.1182/blood.2020008727
First Edition
Ayako Nakamura-Ishizu; Desmond Chin; Takayoshi Matsumura; Darren Qiancheng Tan; Makiko Kashio Mochizuki; Deng Jianwen; Toshio Suda
DOI: 10.1182/blood.2020005517
Clinical Trials and Observations
Carmelo Gurnari; Jaroslaw P Maciejewski
DOI: 10.1182/blood.2021010898


Remembering Art Nienhuis, MD
Former Blood EIC (1988 – 1992)

Featured Content

Blood Podcast: Season 2, Episode 8

In this week’s episode, we will learn more about pre-clinical work that aims to identify optimal immunotargets for treatment of pediatric AML, report on a novel path for subcutaneous administration of Factor 8, and highlight the performance characteristics of the platelet factor 4-dependent p-selectin expression assay for the diagnosis of heparin-induced thrombocytopenia.

CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

Willier and colleagues report that the expression of target molecules for immunotherapy in pediatric acute myeloid leukemia (AML) differs from expression profiles in adult AML. On the basis of their study of 36 cases, they identify CLEC12A and CD33 as preferential immunotargets for combined targeting in pediatric AML. They also nominate the combination of CD33 and FLT3 as immunotargets specific for KMT2A-mutated infant AML.

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

How long patients with chronic lymphocytic leukemia (CLL) should receive ibrutinib-based first-line therapy is unknown. Michallet and colleagues provide an update of an ongoing phase 2 trial, reporting that those patients who achieve complete remission and have no minimal residual disease (MRD) have robust benefit at 3 years after 15 months of fixed-duration therapy. These data add weight to the idea that MRD-guided therapy may assist in optimizing personalized therapy for patients with CLL.

Antibody-induced procoagulant platelets in severe COVID-19 infection

The prothrombotic state observed in patients with COVID-19 has many dimensions. Althaus et al identify circulating procoagulant platelets in patients with severe disease and demonstrate that immunoglobulin G antibodies induced in response to SARS-CoV-2 can activate platelets by triggering apoptosis. Correlative associations suggest that this is relevant for thrombus formation in patients with severe disease.

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

Management of hemophilia A depends on repeated intravenous injections of factor VIII, and development of effective sub- cutaneous delivery is desirable but challenging. Vollack-Hesse et al describe the use of recombinant von Willebrand factor fragments to protect factor VIII from phospholipids in subcutaneous tissues, increasing bioavailability and hemostatic activity but not antigenicity in murine models. These data provide the rationale for clinical trials of this strategy.

A prospective, blinded study of a PF4-dependent assay for HIT diagnosis

Diagnosis of heparin-induced thrombocytopenia (HIT) can be a challenge. Pathogenic HIT antibodies selectively activate platelet factor 4 (PF4)–treated platelets. In a prospective, blinded study of more than 400 patients suspected of having HIT, Samuelson Bannow and colleagues demonstrate high accuracy of the technically simple PF4-dependent P-selectin expression assay (PEA) relative to the gold standard (serotonin release assay). Widespread use of the PEA could improve diagnosis and change clinical practice.

Close Modal

or Create an Account

Close Modal
Close Modal